Darzalex

Darzalex (daratumumab) is a monoclonal antibody used in the treatment of multiple myeloma. This subcutaneous medication targets specific proteins to help manage certain blood cancers.

Darzalex is primarily used for the treatment of multiple myeloma, a type of blood cancer. It works by targeting a protein called CD38, which is found on the surface of myeloma cells. This helps the immune system recognize and destroy these cancerous cells. Daratumumab is often used in combination with other treatments to manage this condition.

Common effects of Darzalex may include infusion-related reactions such as fever, chills, and shortness of breath. Some patients may also experience fatigue, nausea, or upper respiratory tract infections. These effects can vary from person to person and are not experienced by everyone.

Darzalex should be administered under the supervision of a healthcare professional. It is important to inform your healthcare provider about any existing medical conditions or allergies before starting treatment. Regular monitoring may be required to manage potential side effects.

Darzalex may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and certain foods may also affect how Darzalex works, so it is advisable to follow specific dietary guidelines provided by your healthcare professional.